DURHAM, NC, August 25, 2021 – BioAgilytix Labs, LLC (BioAgilytix), a leading global contract research organization focused on supporting pharmaceutical and biotech partners in all phases of drug development, was recently ranked number 1939 on Inc.’s annual Inc. 5000 list, the most prestigious ranking of the nation’s fastest-growing private companies. The list represents a unique look at the most successful companies within the American economy, and 2021 marks BioAgilytix’s eighth appearance on the list since 2013. The annual list recognizes the most innovative and entrepreneurial businesses in the country, providing a ranking of private, for-profit and independent companies that achieved significant percentage growth of annual revenue over the three previous years. This year, BioAgilytix ranked among the top half of companies, charting at #1939. 2021 reflects continued ranking improvement, as the most recent two years ranked BioAgiltyix at #2951 (2020) and #1968 (2019).

Between 2018-2020, BioAgilytix proudly supported more than 35% of all biologics approved by the FDA, with the company expecting that number to grow dramatically with its continued strategy of smart, aligned growth.

“Congratulations once again to Team BioAgilytix, as their efforts landed us on the prestigious 2021 Inc. 5000 list,” said Jim Datin, President and Chief Executive Officer of BioAgilytix. “We have a vision to be the world’s most comprehensive bioanalytical services company and recently expanded our service offerings with the acquisition of San Diego-based MicroConstants. We’re excited to add more than 110 seasoned colleagues with unique and complementary expertise in regulated bioanalysis and DMPK for small and large molecule therapeutics, plus novel technology platforms and proximity to the West Coast’s high-value pharma and biotech market. In addition, we also announced a definitive agreement to purchase 360biolabs^®, the most comprehensive contract research organization in Australia, expanding our global footprint into a jurisdiction of choice to commence first-in-human trials (FIH) and early-phase clinical trials. 2021 is certainly proving to be a pivotal year, but 2022 looks even brighter and busier as we integrate, cross-pollinate and share knowledge and methods across our global network of laboratories – all to benefit our customers and the patients they serve!”

Not only have companies on the 2021 Inc. 5000 performed very competitively within their markets, but given 2020’s unprecedented challenges, those named to this year’s list also proved especially resilient and flexible. Among the 5,000, the average median three-year growth rate soared to 543 percent, and median revenue reached $11.1 million. Together, those companies added more than 610,000 jobs to the economy over the past three years.

Complete results of the Inc. 5000, including company profiles and an interactive database that can be sorted by industry, region and other criteria, can be found at www.inc.com/inc5000. The top 500 companies are featured in the September print issue of Inc.

“The 2021 Inc. 5000 list feels like one of the most important rosters of companies ever compiled,” says Scott Omelianuk, Editor-in-Chief of Inc. “Building one of the fastest-growing companies in America in any year is a remarkable achievement. Building one in the crisis we’ve lived through is just plain amazing. This kind of accomplishment comes with hard work, smart pivots, great leadership, and the help of a whole lot of people.”

About BioAgilytix

BioAgilytix is a leading global contract research organization focused on supporting pharmaceutical and biotech partners in all phases of drug development. With laboratory locations in North Carolina’s Research Triangle Park; Cambridge, Massachusetts; San Diego, California and Hamburg, Germany, BioAgilytix provides PK, immunogenicity, biomarkers, and cell-based assay services supporting the development and release testing of biologics across a number of industries and disease states.

BioAgilytix offers assay development, validation, and sample analysis under non-GLP, GLP, and GCP, as well as GMP quality control testing (i.e., product release testing, stability testing, etc.) BioAgilytix also offers diagnostic testing services at its CLIA-certified, CAP-accredited Boston laboratory.

BioAgilytix’s team of highly experienced scientific and QA professionals ensures high-quality science, data integrity and regulatory compliance through all phases of clinical development. BioAgilytix is a trusted partner to many top global pharmaceutical and biotech companies. For more information, visit bioagilytix.com.